A new technique, quantitative T1 mapping with cardiovascular MRI, can help clinicians detect Fabry disease and the severity of heart damage.
T1 mapping can help detect Fabry disease (FD) and the severity of resulting heart damage, earlier than other types of MRI, according to an article in Circulation – Cardiovascular Imaging.
"Heart disease is the number one cause of death for patients with Fabry disease. The earlier the disease can be pinpointed, the sooner treatment can start,” co-author Gavin Y. Oudit, MD, PhD, said in a release. “The treatment for the disease halts the condition and prevents serious damage to the heart."
In an effort to improve current imaging evaluations of the heart for these patients, researchers from the Alberta Heart Institute at the University of Alberta in Edmonton, Canada, developed a new technique: quantitative T1 mapping with cardiovascular MRI. They, then, undertook a small study to assess its potential as a disease-specific imaging biomarker.
A total of 75 subjects participated in the study: 31 patients with FD, 23 controls, and 21 subjects with concentric remodeling or hypertrophy. All participants underwent cardiovascular MRI to measure left ventricular (LV) morphology, function, delayed enhancement, as well as myocardial T1 values, and derived parameters (extracellular volume).
Results showed that all had LV ejection fraction greater than 50 percent and similar volumes. FD and concentric remodeling or hypertrophy had similarly increased mass, wall thickness, and mass/volume as compared with controls.
Of the 31 patients with FD, 16 had LV hypertrophy, as did 10 of the 21 with concentric remodeling or hypertrophy. The researchers found that non-contrast myocardial T1 values were substantially lower in the patients with FD as compared with the controls and those with concentric remodeling or hypertrophy, but extracellular volume was similar in all groups
Women had lower LV mass and wall thickness, longer myocardial T1 values, and larger extracellular volume suggesting a key sex difference in cardiac remodeling.
"This test can uniquely identify Fabry disease by detecting microscopic changes in the heart muscle structure that are not visible on regular images," co-author Richard B. Thompson, PhD, said. "Fabry disease can look like other diseases if you only look at the whole heart structure or function, but this T1 mapping test, that can detect the tiniest changes in the heart, could identify all the patients with Fabry disease."
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
Is MRI Contrast Enhancement Necessary for Long-Term Monitoring of Diffuse Glioma?
March 4th 2025In a comparison of contrast-enhanced T1-weighted (CET1w) MRI (and T2-weighted MRI/FLAIR imaging, researchers found that only three out of 82 cases of glioma progression were solely detected with CET1w MRI.
Emerging AI Software for Prostate MRI Offers 95 Percent Sensitivity for csPCa
February 28th 2025In a multicenter study involving over 1,000 patients, a deep learning software offered comparable sensitivity and specificity for Gleason grade group > 2 tumors in comparison to radiologist interpretation.